162

BIOLOGICAL2 trials

Sponsors

Yangshengtang Co., Ltd

Conditions

Chronic Hepatitis BChronic Hepatitis B Virus Infection

Phase 1

Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects

CompletedNCT05310487

Yangshengtang Co., LtdChronic Hepatitis B

Start: 2022-09-30End: 2023-10-22Updated: 2023-11-27

A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection

TerminatedNCT06159062

Yangshengtang Co., LtdChronic Hepatitis B Virus Infection

Start: 2024-06-03End: 2024-07-09Updated: 2024-07-16